Similar articles

• [Dopamine agonists in the therapy of parkinson syndrome].

  Kapfhammer HP, Rüther E. Kapfhammer HP, et al. Nervenarzt. 1985 Feb;56(2):69-81. Nervenarzt. 1985. PMID: 3982566 German. No abstract available.
• Dopamine agonists and Parkinson's disease.

  Burton K, Calne DB. Burton K, et al. Clin Neurol Neurosurg. 1984;86(3):172-7. doi: 10.1016/0303-8467(84)90194-x. Clin Neurol Neurosurg. 1984. PMID: 6091965
• Levodopa in the treatment of Parkinson's disease: current controversies.

  Gerlach M, Reichmann H, Riederer P. Gerlach M, et al. Mov Disord. 2005 May;20(5):643; author reply 643-4. doi: 10.1002/mds.20435. Mov Disord. 2005. PMID: 15732130 No abstract available.
• [Considerations in the drug treatment of parkinsonism (author's transl)].

  Hungerbühler JP, Regli F. Hungerbühler JP, et al. Schweiz Rundsch Med Prax. 1978 Nov 7;67(45):1648-57. Schweiz Rundsch Med Prax. 1978. PMID: 30976 Review. French. No abstract available.
• Dopamine receptor stimulating agonists in the treatment of Parkinson's disease.

  Agid Y, Barroche G, Bonnet AM, Javoy-Agid F, Kato G, Lhermitte F, Pollak P, Signoret JL. Agid Y, et al. Biomedicine. 1979 Jun;30(2):67-71. Biomedicine. 1979. PMID: 383169 Review.